
On August 14, 2023, Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that the United States (U.S.) Food and Drug Administration (FDA) has approved the first therapeutic indication for DAXXIFY® (DaxibotulinumtoxinA-Lanm) for injection for the treatment of cervical dystonia in adults.7 DAXXIFY®, powered by Peptide Exchange Technology™, was previously approved by the FDA for the temporary improvement […]